The effect of letrozole and N-acetylcysteine in the treatment of infertility in patients with polycystic ovary syndrome

Comparison of the effect of letrozole with N-acetylcysteine on the expression levels of genes involved in glucose metabolism and the proliferation of cumulus cells in patients with polycystic ovarian syndrome.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221019056244N1

Enrollment

Registered

2023-03-30

Start date

2023-03-21

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: "Intervention group1:" This group receive a daily dose of 1500 mg of Metformin (Tehran Chemie Pharmaceutical Company) along with 5 mg of letrozole (Iran Hormon Pharmaceutical Company)

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Ovulation disorder (oligo ovulation or anovulation). Clinical or laboratory evidence of high testosterone levels Morphology of polycystic ovary in ultrasound Normal thyroid function Normal prolactin test At least one year has passed since the patient's infertility. Normal analysis of the patient’s husband’s semen

Exclusion criteria

Exclusion criteria: Thyroid dysfunction. Uterine abnormalities leading to infertility Ovarian cysts larger than 6 centimeters. History of asthma. Taking any drug effective in glucose metabolism Abnormality of prolactin tests

Design outcomes

Primary

Measure	Time frame
Hyaluronan synthase 2 gene expression level. Timepoint: About 14 days after the start of the treatment, we will not measure at the beginning of the study. Method of measurement: Polymerase chain reaction device.;Versican gene expression level. Timepoint: About 14 days after the start of the treatment, we will not measure at the beginning of the study. Method of measurement: Polymerase chain reaction device.	—

Measure

Time frame

Hyaluronan synthase 2 gene expression level. Timepoint: About 14 days after the start of the treatment, we will not measure at the beginning of the study. Method of measurement: Polymerase chain reaction device.;Versican gene expression level. Timepoint: About 14 days after the start of the treatment, we will not measure at the beginning of the study. Method of measurement: Polymerase chain reaction device.

—

Secondary

Measure	Time frame
Phosphofructokinase, Platelet gene expression level. Timepoint: About 14 days after the start of the treatment, we will not measure at the beginning of the study. Method of measurement: Polymerase chain reaction device.;Pyruvate kinase M2 gene expression level. Timepoint: About 14 days after the start of the treatment, we will not measure at the beginning of the study. Method of measurement: Polymerase chain reaction device.	—

Measure

Time frame

Phosphofructokinase, Platelet gene expression level. Timepoint: About 14 days after the start of the treatment, we will not measure at the beginning of the study. Method of measurement: Polymerase chain reaction device.;Pyruvate kinase M2 gene expression level. Timepoint: About 14 days after the start of the treatment, we will not measure at the beginning of the study. Method of measurement: Polymerase chain reaction device.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Pashaei Asl

Tabriz University of Medical Sciences

pashaim@tbzmed.ac.ir+98 41 3553 9161

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026